GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum Genomics (STU:2QG) » Definitions » EV-to-EBIT

Quantum Genomics (STU:2QG) EV-to-EBIT : 0.11 (As of Jun. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Quantum Genomics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Quantum Genomics's Enterprise Value is €-3.36 Mil. Quantum Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was €-30.46 Mil. Therefore, Quantum Genomics's EV-to-EBIT for today is 0.11.

The historical rank and industry rank for Quantum Genomics's EV-to-EBIT or its related term are showing as below:

STU:2QG's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.76
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Quantum Genomics's Enterprise Value for the quarter that ended in Dec. 2022 was €-3.99 Mil. Quantum Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was €-30.46 Mil. Quantum Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was 763.87%.


Quantum Genomics EV-to-EBIT Historical Data

The historical data trend for Quantum Genomics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum Genomics EV-to-EBIT Chart

Quantum Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.14 -4.64 -7.49 -5.56 0.11

Quantum Genomics Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.49 - -5.56 - 0.11

Competitive Comparison of Quantum Genomics's EV-to-EBIT

For the Biotechnology subindustry, Quantum Genomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantum Genomics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quantum Genomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quantum Genomics's EV-to-EBIT falls into.



Quantum Genomics EV-to-EBIT Calculation

Quantum Genomics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-3.362/-30.463
=0.11

Quantum Genomics's current Enterprise Value is €-3.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Quantum Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was €-30.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum Genomics  (STU:2QG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Quantum Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 ) =EBIT / Enterprise Value (Q: Dec. 2022 )
=-30.463/-3.98796836
=763.87 %

Quantum Genomics's Enterprise Value for the quarter that ended in Dec. 2022 was €-3.99 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Quantum Genomics's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was €-30.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum Genomics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Quantum Genomics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum Genomics (STU:2QG) Business Description

Traded in Other Exchanges
N/A
Address
33, Rue Marbeuf, Paris, FRA, 75008
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.

Quantum Genomics (STU:2QG) Headlines

No Headlines